Patient response and resource management: Another view of clozapine treatment of schizophrenia

American Journal of Psychiatry

Volumn 152, Issue 6, 1995, Pages 827-832

  Carpenter Jr , William T ^a   Conley, Robert R ^a   Buchanan, Robert W ^a   Breier, Alan ^a   Tamminga, Carol A ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

ARTICLE; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; EXTRAPYRAMIDAL SYMPTOM; GRANULOCYTOSIS; HOSPITALIZATION; HUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0029064332     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.152.6.827     Document Type: Article

References (48)

1. Claghorn J, Honigfeld G, Abuzzahab FS Sr, Wang R, Steinbook R, Tuason V, Klerman G: The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987; 7:377-384
2. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
3. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH: Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49:345-353
4. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151:20-26
5. Shore D, Matthews S, Cott J, Lieberman JA: The clinical implications of clozapine discontinuation. Schizophr Bull (in press)
6. Angrist B, Schulz SC (eds): The Neuroleptic-Nonresponsive Patient: Characterization and Treatment. Washington, DC, American Psychiatric Press, 1990, pp xvii-xxviii
7. Kane JM, Marder SR: Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993; 19:287-302
8. Fischer-Cornelssen KA, Ferner UJ: An example of European multi-center trials: multispectral analysis of clozapine. Psychopharmacol Bull 1976; 12:34-39
9. Wilson WH: Clinical review of clozapine treatment in a state hospital. Hosp Community Psychiatry 1992; 43:700-703
10. Zito JM, Volavka J, Craig TJ, Czobor P, Banks S, Vitrai J: Pharmacoepidemiology of clozapine in 202 inpatients with schizophrenia. Ann Pharmacother 1993; 27:1262-1269
11. Chiu E, Burrows G, Stevenson J: Double-blind comparison of clozapine and chlorpromazine in acute schizophrenic illness. Aust NZ J Psychiatry 1976; 10:343-347
12. Guirguis E, Voineskos G, Gray J, Schlieman E: Clozapine (Leponex) vs chlorpromazine (Largactil) in acute schizophrenia (a double-blind controlled study). Curr Ther Res 1977; 21:707-719
13. Shopsin B, Klein H, Aaronson M, Collora M: Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison. Arch Gen Psychiatry 1979; 36:657-664
14. Gelenberg AJ, Doller JC: Clozapine versus chlorpromazine for the treatment of schizophrenia: preliminary results from a double-blind study. J Clin Psychiatry 1979; 40:238-240
15. Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM: Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994; 55:102-106
16. Meltzer HY, Burnett S, Bastani B, Ramirez LF: Effect of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990; 41: 892-897
17. Miller DD, Perry PJ, Cadoret R, Andreasen NC: A two and one-half year follow-up of treatment-refractory schizophrenics treated with clozapine. Biol Psychiatry (Suppl) 1992; 31:85A
18. Breier A, Buchanan RW, Irish D, Carpenter WT Jr: Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hosp Community Psychiatry 1993; 44: 1145-1149
19. Baldessarini RJ, Frankenburg FR: Clozapine: a novel antipsychotic agent. N Engl J Med 1991; 324:746-754
20. Goldberg SC: Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 1985; 11:453-456
21. Meltzer HY, Sommers AA, Luchins DJ: The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J Clin Psychopharmacol 1986; 6:329-338
22. Opler LA, Albert D, Ramirez PM: Psychopharmacologic treatment of negative schizophrenic symptoms. Compr Psychiatry 1994; 35:16-28
23. Lindstrom LH: The effect of long term treatment of clozapine in schizophrenia: a retrospective study of 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 1988; 77: 524-529
24. Meltzer HY: Dimensions of outcome with clozapine. Br J Psychiatry 1992; 160(suppl 17):46-53
25. McLarnon MC: Delayed response: Jeff L, in Clozapine: A Compendium of Selected Readings. Edited by Yesavage J. East Hanover, NJ, Sandoz Pharmaceuticals, 1992
26. Meltzer HY, Bastani B, Kwon KY, Ramirez LF, Burnett S, Sharpe J: A prospective study of clozapine in treatment-resistant schizophrenic patients, I: preliminary report. Psychopharmacology (Berl) 1989; 99(suppl):S68-S72
27. Carpenter WT, Heinrichs DW, Alphs LD: Treatment of negative symptoms. Schizophr Bull 1985; 11:440-452
28. Carpenter WT: The negative symptom challenge. Arch Gen Psychiatry 1992; 49:236-237
29. Carpenter WT Jr, Heinrichs DW, Wagman AMI: Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988; 145:578-583
30. Tandon R, Goldman RS, Goodson J, Greden JF: Mutability and relationship between positive and negative symptoms during neuroleptic treatment. Biol Psychiatry 1990; 27:1323-1326
31. Tandon R, Ribeiro SCM, DeQuardo JR, Goodman RS, Goodson J, Greden JF: Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: a replication. Biol Psychiatry 1993; 34:495-497
32. van Kammen DP, Hommer DW, Malas KL: Effect of pimozide on positive and negative symptoms in schizophrenic patients: are negative symptoms state dependent? Neuropsychobiology 1987; 18:113-117
33. Kane J, Mayerhoff D: Do negative symptoms respond to pharmacologic treatment? Br J Psychiatry 1989; 55(suppl 7):115-118
34. Honigfeld G, Patin J: Predictors of response to clozapine therapy. Psychopharmacology (Berl) 1989; 99:564-567
35. Meltzer HY: Clozapine: pattern of efficacy in treatment-resistant schizophrenia, in Novel Antipsychotic Drugs. Edited by Meltzer HY. New York, Raven Press, 1992
36. Buchanan RW, Carpenter WT: Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. J Nerv Ment Dis 1994; 182:193-204
37. Miller DD, Perry PJ, Cadoret RJ, Andreasen NC: Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Compr Psychiatry 1994; 35:8-15
38. Tandon R, Goldman R, DeQuardo JR, Goldman M, Perez M, Jibson M: Positive and negative symptoms covary during clozapine treatment in schizophrenia. J Psychiatr Res 1993; 27:341-347
39. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM: Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151:1744-1752
40. Conley R, Gounaris C, Tamminga C: Clozapine response varies in deficit versus non-deficit schizophrenic subjects. Biol Psychiatry 1994; 35:746-747
41. Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B: Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991; 17:247-261
42. Meltzer HY: Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull 1992; 18:515-542
43. Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies M, Snitz B: Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993; 150:1630-1638
44. Revicki DA, Luce BR, Wechsler JM, Brown RE, Adler MA: Cost-effectiveness of clozapine in treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990; 41:850-854
45. Reid WH, Mason M, Toprac M: Savings in hospital bed-days related to treatment with clozapine. Hosp Community Psychiatry 1994; 45:261-264
46. Meltzer HY: Effect of clozapine upon the occupational status of treatment-resistant schizophrenic patients, in Clozapine: A Compendium of Selected Readings. Edited by Yesavage J. East Hanover, NJ, Sandoz Pharmaceuticals, 1992
47. Marder SR, Van Putten T: Who should receive clozapine? Arch Gen Psychiatry 1988; 45:865-867
48. Pickar D, Owen RR Jr, Litman RE, Hsiao JK, Su TP: Predictors of clozapine response in schizophrenia. J Clin Psychiatry 1994; 55(Sept suppl B):129-132